Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study

by Zacks Equity Research

Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.

    Seattle Genetics Begins Phase II Study of Cancer Candidate

    by Zacks Equity Research

    Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.

      Arpita Dutt headshot

      5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

      by Arpita Dutt

      Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.

        Cancer Space Last Week Update: Pipeline Expansion in Focus

        by Zacks Equity Research

        Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

          Arpita Dutt headshot

          Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal

          by Arpita Dutt

          The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.

            Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute

            by Zacks Equity Research

            Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.

              4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

              by Zacks Equity Research

              The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

                Johnson & Johnson Files sNDA for Label Expansion of Invokana

                by Zacks Equity Research

                Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.

                  Lilly (LLY) Makes Leadership Changes to Executive Positions

                  by Zacks Equity Research

                  Eli Lilly and Company (LLY) makes some executive appointments for various departments.

                    Radius (RDUS) Enrols First Patient in Breast Cancer Study

                    by Zacks Equity Research

                    Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.

                      Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe

                      by Zacks Equity Research

                      Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.

                        Madeleine Johnson headshot

                        Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why

                        by Madeleine Johnson

                        On Tuesday, shares of biopharmaceutical company Axovant Sciences Ltd. (AXON) have crashed, and the stock is currently down over 70% to $6.72 per share in late-morning trading after it said that its experimental Alzheimer's drug failed a key late-stage trial.

                          Arpita Dutt headshot

                          3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

                          by Arpita Dutt

                          With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.

                            J&J's Arthritis Candidate Sirukumab Denied FDA Approval

                            by Zacks Equity Research

                            J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs

                              by Arpita Dutt

                              Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.

                                Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer

                                by Zacks Equity Research

                                Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.

                                  Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

                                  by Zacks Equity Research

                                  Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

                                    by Arpita Dutt

                                    Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

                                      4 Biotech Stocks That Show Promise on Sustainable Growth

                                      by Zacks Equity Research

                                      Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

                                        Array's NDAs for Melanoma Combo Accepted for Review by FDA

                                        by Zacks Equity Research

                                        Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.

                                          AbbVie's RA Candidate Meets Primary Endpoint in Phase III

                                          by Zacks Equity Research

                                          AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

                                            Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth

                                            by Zacks Equity Research

                                            Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018

                                              by Arpita Dutt

                                              Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.

                                                Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer

                                                by Zacks Equity Research

                                                Merck's (MRK) Keytruda received approval in the EU for the first and second line treatment of certain patients with advanced bladder cancer.

                                                  Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018

                                                  by Zacks Equity Research

                                                  Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018.